| Page 1285 | Kisaco Research
 

Camillo Ricordi

Scientific Advisor
Lipogems International

Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI) and the Cell Transplant Program. Dr.

Camillo Ricordi

Scientific Advisor
Lipogems International

Camillo Ricordi

Scientific Advisor
Lipogems International

Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI) and the Cell Transplant Program. Dr. Ricordi been serving as Responsible Head of the NIH-funded cGMP (current Good Manufacturing Practices) Human Cell Processing Facility (1993-present), for the manufacturing of advanced human cell and other biologic products, for research and clinical applications at the University of Miami, in the U.S. and worldwide. Dr. Ricordi has also served as Senior Associate Dean for Research (2003-2006) and chaired the Dean’s Research Cabinet (2006-2012) at the UM Miller School of Medicine.

 

Thomas Serena

Founder & CEO
SerenaGroup

Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School.

Thomas Serena

Founder & CEO
SerenaGroup

Thomas Serena

Founder & CEO
SerenaGroup

Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School.

To date he has opened and operates wound care centers across the United Sates and globally. Dr. Serena has been the lead or Principal investigator in over 100 clinical trials, including gene therapy for critical limb ischemia, antimicrobial dressings, growth factors, topical and parenteral antibiotics and CTP therapy. He founded the first wound healing cooperative research group that produced more than 12 manuscripts in 2016 alone. In 2011 he developed a diagnostic technique that now bears his name (The Serena Technique©). He holds numerous patents on wound care devices and dressings.

He is recognized internationally as an expert in the field of wound healing: He has more than 200 published papers and has given more than 1000 invited lectures throughout the world. He has published three medical textbooks and authored numerous book chapters. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President-Elect. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association.

Dr. Serena has done extensive medical relief work with Health Volunteers Overseas and served as chairman of the AAWC Global Volunteers/HVO Steering Committee until 2016. In 2016 in partnership with HEAL Foundation he opened a wound clinic in Ho Chi Minh, Vietnam. Outside of wound healing, he consulted for the government of Rwanda on AIDS prevention research.

 

Davide Vigano

Co-founder and CEO
Sensoria Health

Sensoria designs, develops and produces bio-sensing wearable garments. The vision of the company is that the Garment itself will become the next ultra-personal, mobile computer. Davide is a former Microsoft partner level executive with over 25 years of sales, marketing and extensive product management experience. As an intern he started the international localization group for MacWorks and MacOffice in 1987. More recently, he served as General Manager of the Health Solutions Group where he was in charge of marketing and product strategy for both HealthVault and the Amalga product line.

Davide Vigano

Co-founder and CEO
Sensoria Health

Davide Vigano

Co-founder and CEO
Sensoria Health

Sensoria designs, develops and produces bio-sensing wearable garments. The vision of the company is that the Garment itself will become the next ultra-personal, mobile computer. Davide is a former Microsoft partner level executive with over 25 years of sales, marketing and extensive product management experience. As an intern he started the international localization group for MacWorks and MacOffice in 1987. More recently, he served as General Manager of the Health Solutions Group where he was in charge of marketing and product strategy for both HealthVault and the Amalga product line. He acted as Vice President of the Worldwide SMSP Medium Business division which he grew 18% YOY to over $14B. Davide also managed the Italian Marketing, Business and Enterprise operations for five years and brought it to number one in the world for contribution margin, 6th largest Microsoft subsidiary in the world by revenues.

 

Howard Walthall

CEO
Lumiheal Therapeutics

Howard Walthall is the CEO of Lumiheal Therapeutics.  He is an experienced Regenerative Medicine and MedTech entrepreneur with proven success developing and positioning new products and building effective Sales, Marketing, R&D and Operational teams. Howard was previously the CEO of the NuTech companies, which built a regenerative medicine business focusing on surgical and wound care applications, and Executive Vice President for Organogenesis, Inc, which acquired NuTech in 2017.

Howard Walthall

CEO
Lumiheal Therapeutics

Howard Walthall

CEO
Lumiheal Therapeutics

Howard Walthall is the CEO of Lumiheal Therapeutics.  He is an experienced Regenerative Medicine and MedTech entrepreneur with proven success developing and positioning new products and building effective Sales, Marketing, R&D and Operational teams. Howard was previously the CEO of the NuTech companies, which built a regenerative medicine business focusing on surgical and wound care applications, and Executive Vice President for Organogenesis, Inc, which acquired NuTech in 2017.

 

Gregory Schultz

Professor
University of Florida

Gregory Schultz, PhD, is Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida. A major area of his research focuses on defining the role of bacterial biofilms in stimulating chronic inflammation and proteases that impair healing in chronic wounds. Dr.

Gregory Schultz

Professor
University of Florida

Gregory Schultz

Professor
University of Florida

Gregory Schultz, PhD, is Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida. A major area of his research focuses on defining the role of bacterial biofilms in stimulating chronic inflammation and proteases that impair healing in chronic wounds. Dr. Schultz has co-authored 400 scientific publications that have been cited over 17,000 times, has received $38 million grant support as Principal Investigator or Co-investigator, is an inventor on 31 patents, and is a co-founder of two biotech companies in the areas of antimicrobial coatings and antiscarring drugs. He served as President of the Wound Healing Society (1999-2001) and as a member of the National Pressure Ulcer Advisory Panel (2007-2010).

 

Mitchell Sanders

Chief Scientific Officer
Alira Health

Serial Entrepreneur, C-Level Executive, and Scientist developing advanced wound care products for the past 30 years with 15 peer reviewed publications and 45 world-wide patents.  Dr. Sanders was founder and CEO of ECI Biotech (1998-2016) and his company developed the first infection diagnostic for chronic wounds (Bacterial Status), sold by WoundChek Labs.  Dr. Sanders is currently the Chief Scientific Officer of Alira Health, and Executive Vice President of the Product Development Lab. Over the past 20 years Dr.

Mitchell Sanders

Chief Scientific Officer
Alira Health

Mitchell Sanders

Chief Scientific Officer
Alira Health

Serial Entrepreneur, C-Level Executive, and Scientist developing advanced wound care products for the past 30 years with 15 peer reviewed publications and 45 world-wide patents.  Dr. Sanders was founder and CEO of ECI Biotech (1998-2016) and his company developed the first infection diagnostic for chronic wounds (Bacterial Status), sold by WoundChek Labs.  Dr. Sanders is currently the Chief Scientific Officer of Alira Health, and Executive Vice President of the Product Development Lab. Over the past 20 years Dr. Sanders has secured over $50M in strategic partnerships for new product development. Dr. Sanders earned his undergraduate degree in Biology from Boston University, followed by a MS and PhD in Biology and Biomedical Sciences at Worcester Polytechnic Institute (WPI). His postdoctoral training was at MIT/Whitehead Institute in Biochemistry and Host Pathogen Interactions.

 

Michael Schurr

Founder and Chief Medical Officer
Imbed Biosciences

Prof. Michael Schurr, MD is a burn and trauma surgeon and general surgeon at Mission Hospitals, Asheville, NC. Dr. Schurr is board certified in general surgery and surgical critical care. He has joined Mission Hospitals as Director of Inpatient Surgical Wound Care in Dec 2014. Prior to that he practiced for more than 15 years at the School of Medicine in University of Wisconsin-Madison and University of Colorado-Denver. He brings 27 years of experience in advanced care of chronic ulcers, burns and trauma wounds.

Michael Schurr

Founder and Chief Medical Officer
Imbed Biosciences

Michael Schurr

Founder and Chief Medical Officer
Imbed Biosciences

Prof. Michael Schurr, MD is a burn and trauma surgeon and general surgeon at Mission Hospitals, Asheville, NC. Dr. Schurr is board certified in general surgery and surgical critical care. He has joined Mission Hospitals as Director of Inpatient Surgical Wound Care in Dec 2014. Prior to that he practiced for more than 15 years at the School of Medicine in University of Wisconsin-Madison and University of Colorado-Denver. He brings 27 years of experience in advanced care of chronic ulcers, burns and trauma wounds. He has successfully led clinical trials of several advanced wound dressings and hernia surgical meshes

 

Vickie Driver

System Chief, Wound Healing and Hyberbaric Medicine Centers
Inova Health System

Vickie R. Driver, DPM, MA, FACFAS, FAAWC, is board certified with the American Board of Podiatric Surgeons and is a Fellow at the American College of Foot and Ankle Surgeons. She is the System Medical Director of the Inova Wound Healing Centers. Dr. Driver has found treating patients and helping them get better to be one of the greatest honors of her life. She takes caring for patients seriously and practices based on the latest evidence and research available.

Vickie Driver

System Chief, Wound Healing and Hyberbaric Medicine Centers
Inova Health System

Vickie Driver

System Chief, Wound Healing and Hyberbaric Medicine Centers
Inova Health System

Vickie R. Driver, DPM, MA, FACFAS, FAAWC, is board certified with the American Board of Podiatric Surgeons and is a Fellow at the American College of Foot and Ankle Surgeons. She is the System Medical Director of the Inova Wound Healing Centers. Dr. Driver has found treating patients and helping them get better to be one of the greatest honors of her life. She takes caring for patients seriously and practices based on the latest evidence and research available.

She also serves as the Co-Director of the Limb Preservation Center and Director of Wound Care and Hyperbaric Research for Inova Heart and Vascular Institute. She has been involved with clinical research across the globe for more than 20 years, seeking to find the very best diagnostics and treatments for patients at high risk of limb loss. Dr. Driver has coauthored more than 150 publications and abstracts.

Dr. Driver has recently been selected as a Fellow of the Royal College of Physicians and Surgeons-Glasgow, PM and is an Inaugural Fellow of the Association for the Advancement of Wound Care (FAAWC). Dr. Driver recently accepted the position as Chair of the Wound Care Collaborative Community, an important collaboration with the U.S Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services and has received the Robert A. Warriner III, MD, Memorial Award. Her career has a special emphasis on wound healing and limb preservation, and she is proud to be an outspoken ambassador for improving care to patients that face the burden of limb loss.

Dr. Driver is a former Professor of Surgery in the Department of Orthopedics at Brown University in Providence, RI, and Associate Professor of Surgery at Boston University. She currently serves as Honorary Visiting Professor at Cardiff University (UK) in the Department of Medicine and Professor at Barry University (USA). She proudly serves as a member of the Wound Healing Society’s board of directors and as a member of the board of directors for the Critical Limb Ischemia Global Society, where she also chairs the wound healing committee. She has recently completed her tenure as President of the Advancement of Wound Care Association and has served for nine years on the board of directors.

 

Carlo Perez

CEO and Co-Founder
Swift Medical

Swift Medical has become the undisputed leader, defining the category with their empathic, AI-powered technology adopted by over 4,000 healthcare facilities across the continuum of care. A serial entrepreneur with 20 years of engineering and company building experience, Carlo has worked at the forefront of artificial intelligence, machine visioning and robotics. He worked in research and development at Advanced Micro Devices (AMD) Inc., taught computer and electrical engineering as a college professor and is a three time, venture-backed tech founder.

Carlo Perez

CEO and Co-Founder
Swift Medical

Carlo Perez

CEO and Co-Founder
Swift Medical

Swift Medical has become the undisputed leader, defining the category with their empathic, AI-powered technology adopted by over 4,000 healthcare facilities across the continuum of care. A serial entrepreneur with 20 years of engineering and company building experience, Carlo has worked at the forefront of artificial intelligence, machine visioning and robotics. He worked in research and development at Advanced Micro Devices (AMD) Inc., taught computer and electrical engineering as a college professor and is a three time, venture-backed tech founder. With Swift Medical, he’s proud to have built one of the few, 100% diverse boards in the health tech industry. Carlo is a recognized thought leader and speaker in wound care innovation, digital health transformation, value-based care, big data and artificial intelligence, empathetic product design and the innovation economy.

 

Ronald Silverman

Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer
3M Health Care

Dr. Ron Silverman is the Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer for 3M Health Care Business Group. He is also a practicing plastic and reconstructive surgeon at the University of Maryland Medical Center.  Prior to his CMO role, Dr. Silverman was the Chief of Plastic Surgery at the University of Maryland and holds academic appointments at both the University of Maryland and Johns Hopkins Schools of Medicine.

Ronald Silverman

Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer
3M Health Care

Ronald Silverman

Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer
3M Health Care

Dr. Ron Silverman is the Senior Vice President, Global Medical and Clinical Affairs, Health Care Compliance and Chief Medical Officer for 3M Health Care Business Group. He is also a practicing plastic and reconstructive surgeon at the University of Maryland Medical Center.  Prior to his CMO role, Dr. Silverman was the Chief of Plastic Surgery at the University of Maryland and holds academic appointments at both the University of Maryland and Johns Hopkins Schools of Medicine.